Evolving practices, treatment decisions, and unmet needs in intermediate-stage hepatocellular carcinoma: An Asia Pacific perspective

Table 3 Reported availability of national screening programmes and nature of diagnosis among survey responders (n = 70), n (%)

	Overall (n = 70)	Korea (n = 10)	Malaysia (n = 10)	Philippines (n = 10)	Singapore (n = 10)	Taiwan (n = 10)	Thailand (n = 10)	Vietnam (n = 10)
Respondents identifying availability of a national screening programme	N/A1	10 (100.0)	2 (20.0)	-	3 (30.0)	9 (90.0)	7 (70.0)	3 (30.0)
Usual location of HCC diagnosis
Large national hospital	40 (57.1)	5 (50.0)	6 (60.0)	3 (30.0)	8 (80.0)	7 (70.0)	5 (50.0)	6 (60.0)
Mid-sized hospital	21 (30.0)	2 (20.0)	4 (40.0)	3 (30.0)	2 (20.0)	3 (30.0)	5 (50.0)	2 (20.0)
Rural hospital	1 (1.4)	-	-	-	-	-	-	1 (10.0)
Private practice	4 (5.7)	1 (10.0)	-	3 (30.0)	-	-	-	-
Other	4 (5.7)	2 (20.0)	-	1 (10.0)	-	-	-	1 (10.0)
HCP usually diagnosing
GP/PCP	1 (1.4)	-	-	-	-	-	-	1 (10.0)
Medical oncologist	3 (4.3)	-	-	-	-	1 (10.0)	-	2 (20.0)
Gastroenterologist/hepatologist	54 (77.1)	10 (100.0)	6 (60.0)	8 (80.0)	10 (100.0)	9 (90.0)	8 (80.0)	3 (30.0)
Radiologist	8 (11.4)	-	2 (20.0)	2 (20.0)	-	-	2 (20.0)	2 (20.0)
Surgeon	3 (4.3)	-	2 (20.0)	-	-	-	-	1 (10.0)
Other	1 (1.4)	-	-	-	-	-	-	1 (10.0)
Mean estimated proportion of patients diagnosed by stage, %
Early stage (BCLC-0 or -A)	19.8	32.9	10.7	11.8	27.5	28.0	11.5	16.5
Intermediate stage (BCLC-B)	31.7	33.5	28.3	25.2	33.5	27.2	34.7	39.5
Advanced stage (BCLC-C)	32.8	26.6	36.0	39.0	26.0	32.3	40.3	29.5
End stage (BCLC-D)	15.6	7.0	25.0	24.0	13.0	12.5	13.5	14.5

¹Not applicable as data relate to availability of national screening programmes and are therefore country specific.

N/A: Not applicable; HCC: Hepatocellular carcinoma; HCP: Healthcare professional; GP: General practitioner; PCP: Primary care physician; BCLC: Barcelona Clinic Liver Cancer.